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Anticancer compound ABT-263 accelerates apoptosis
in virus-infected cells and imbalances cytokine
production and lowers survival rates of infected mice
L Kakkola1,11, OV Denisova1,11, J Tynell2, J Viilia¨inen3, T Ysenbaert4, RC Matos1, A Nagaraj1, T O¨hman3, S Kuivanen5, H Paavilainen6,
L Feng7, B Yadav1, I Julkunen2, O Vapalahti5,8, V Hukkanen6, J Stenman1,7, T Aittokallio1, EW Verschuren1, PM Ojala3,9, T Nyman3,
X Saelens4, K Dzeyk10 and DE Kainov*,1
ABT-263 and its structural analogues ABT-199 and ABT-737 inhibit B-cell lymphoma 2 (Bcl-2), BCL2L1 long isoform (Bcl-xL) and
BCL2L2 (Bcl-w) proteins and promote cancer cell death. Here, we show that at non-cytotoxic concentrations, these small
molecules accelerate the deaths of non-cancerous cells infected with influenza A virus (IAV) or other viruses. In particular, we
demonstrate that ABT-263 altered Bcl-xL interactions with Bcl-2 antagonist of cell death (Bad), Bcl-2-associated X protein (Bax),
uveal autoantigen with coiled-coil domains and ankyrin repeats protein (UACA). ABT-263 thereby activated the caspase-9-
mediated mitochondria-initiated apoptosis pathway, which, together with the IAV-initiated caspase-8-mediated apoptosis
pathway, triggered the deaths of IAV-infected cells. Our results also indicate that Bcl-xL, Bcl-2 and Bcl-w interact with pattern
recognition receptors (PRRs) that sense virus constituents to regulate cellular apoptosis. Importantly, premature killing of
IAV-infected cells by ABT-263 attenuated the production of key pro-inflammatory and antiviral cytokines. The imbalance in
cytokine production was also observed in ABT-263-treated IAV-infected mice, which resulted in an inability of the immune
system to clear the virus and eventually lowered the survival rates of infected animals. Thus, the results suggest that the
chemical inhibition of Bcl-xL, Bcl-2 and Bcl-w could potentially be hazardous for cancer patients with viral infections.
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ABT-263 and its structural analogues ABT-737 and ABT-199
are small molecules that have significant efficacy
against human lymphoid malignancies and small-cell lung
carcinoma, especially ABT-199, because it does not induce
thrombocytopenia.1,2 These three compounds bind with
different affinities to B-cell lymphoma 2 (Bcl-2), BCL2L1 long
isoform (Bcl-xL) and BCL2L2 (Bcl-w) proteins and displace
Bak, Bad and Bax.3 Bax, Bak and Bad mediate the release of
apoptogenic molecules, including cytochrome c, from the
mitochondria. Cytosolic cytochrome c complexes with apop-
totic protease-activating factor 1 (APAF1), uveal autoantigen
with coiled-coil domains and ankyrin repeats (UACA) and
pro-caspase-9 to form the apoptosome. Caspase-9 becomes
activated in this complex, empowering it to proteolytically
activate 3 and 7, which cleave numerous proteins, including
the downstream executioner pro-caspase-6, which, in turn,
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activates caspase-8.4,5 Active caspase-8 cleaves
BH3-interacting domain death agonist (Bid).6 Cleaved Bid
facilitates the mitochondrial apoptosis pathway and
accelerates cancer cell death.7
Replication of several important human microbes, such as
the influenza A virus (IAV), hepatitis B virus, hepatitis C virus,
Epstein–Barr virus, vesicular stomatitis virus, coronavirus,
Kaposi’s sarcoma-associated herpes virus and human
immunodeficiency virus depend on Bcl-2-, Bcl-xL- and
Bcl-w-mediated mitochondria-initiated apoptosis.8–16 In
addition to mitochondria-initiated apoptosis, the replication
of these microbes is associated with the caspase-8-FADD
(FAS-associating death domain-containing protein)-mediated
apoptosis pathway.17 We hypothesised that the chemical
inhibitors of Bcl-2, Bcl-xL and Bcl-w could accelerate the
death of virus-infected cells by enhancing caspase-mediated
cross-talk between mitochondria and death receptor apoptosis
pathways.
We show that anticancer ABT-263, ABT-737 and ABT-199
accelerate the death of non-cancerous mammalian cells
infected with IAV and other viruses through the mutual
amplification of the caspase-9-mediated mitochondria-
initiated apoptosis by the IAV-initiated caspase-8-mediated
apoptosis. Moreover, we show that the premature cell death
limits the innate immune responses to viral infections and
lowers the survival rates of infected animals. Our results
suggest that ABT-263, ABT-737 and ABT-199 may be
hazardous for cancer patients with viral infections.
Results
Anticancer agent ABT-263 accelerates death of virus-
infected cells. Bcl-xL, Bcl-2 and Bcl-w are components of a
cell-signalling network that governs cell survival and cell
death in response to different stimuli such as viruses. We
hypothesised that chemical inhibitors of Bcl-xL, Bcl-2 and
Bcl-w could modulate the survival and death of virus-infected
cells. We studied the effect of the anticancer agent ABT-263
on the survival of non-cancerous human macrophages in
response to IAV infection.18,19 Cells were treated with
ABT-263, infected with IAV or mock, and cell survival was
monitored at the indicated times. At non-cytotoxic concentra-
tions, ABT-263 accelerated the death of IAV-infected cells
(Figure 1a). The cell death was dependent on the dose of
ABT-263 and on the multiplicity of the viral infection (Figures
1b and c). Interestingly, ABT-263 treatment only slightly
attenuated the production of infectious virus particles
(Figure 1d). Thus, at non-cytotoxic concentrations,
anticancer ABT-263 sensitises non-cancerous cells to
IAV-induced death.
Next we studied the effect of ABT-263 and its analogues on
the death IAV-infected cells. We found that the structural
analogues of ABT-263, ABT-737 and ABT-199 accelerated
the death of IAV-infected human macrophages. By contrast,
two other Bcl-xL-, Bcl-2- and Bcl-w-inhibitors – gossypol and
TW-37 – were ineffective in the sensitisation of cells to IAV-
induced death (Figure 2a; Supplementary Figure 1). The
effect of ABT-263 was not restricted to a specific macrophage
preparation, cell line or IAV strain (Figures 2b and c).
Furthermore, ABT-263 accelerated the death of various
cell types infected with influenza B (Orthomyxoviridae),
Bunyamwera (Bunyaviridae), Semliki Forest and Sindbis
(Togaviridae), Herpes Simplex 1 and 2 (Herpesviridae),
Vaccinia (Poxiviridae), Measles (Paramyxoviridae), echovirus
6 (Picornaviridae), but not with Kaposi’s sarcoma-associated
herpes (Herpesviridae), Tick-borne encephalitis and dengue
viruses (Flaviviridae) (Figure 2d and Supplementary
Figure 2). These results suggest that ABT-263 and its
structural analogues sensitise cells to virus-mediated killing
and confirmed that Bcl-xL, Bcl-2 and Bcl-w are essential for
cell survival upon viral infection.
Potential mechanism of action of ABT-263 in infected
cells. To address the mechanism of action of ABT-263 in
virus-infected cells, we first analysed the stage at which IAV
infection ABT-263 triggers cell death using three known
inhibitors of IAV infection: obatoclax, saliphenylhalamide
and gemcitabine, which target myeloid cell leukaemia-1
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Figure 1 ABT-263 accelerates the death of primary human macrophages. (a) Human monocyte-derived macrophages were non- or ABT-263-treated (0.4mM) and mock-
or IAV-infected (WSN, moi 10), and cell viability was measured using a CTG assay at the indicated time points. (b) Macrophages were treated with increasing concentrations of
ABT-263 and mock- or IAV-infected (WSN, moi 10), and cell viability was measured using a CTG assay 11 h after infection. The DSS was calculated. (c) Macrophages were
non- or ABT-263-treated (0.4mM) and infected with different moi of IAV (WSN), and cell viability was measured using a CTG assay 11 h after infection. (d) Macrophages were
non- or ABT-263-treated (0.4mM) and mock- or IAV-infected (WSN, moi 0.1), and virus production was determined 24 h after infection. All error bars, s.d. (n¼ 3)
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(Mcl-1), vacuolar ATPase (v-ATPase) and ribonucleotide
reductase (RNR), respectively.20,21 Mcl-1 and v-ATPase
are necessary for endocytic uptake of IAV in cytoplasm,
whereas RNR is essential for viral RNA transcription and
replication in the nuclei of infected cells. We found that
obatoclax and saliphenylhalamide, but not gemcitabine,
rescued IAV-infected ABT-263-treated retinal pigment
epithelium (RPE) cells from death (Figures 3a–c). Second,
we performed a time-of-compound-addition experiment,
which demonstrated that ABT-263 killed IAV-infected RPE
cells independently of the time of its addition (Figure 3d).
These results indicate that ABT-263 sensitises cells to
death at multiple stages of IAV infection following virus
endocytic uptake.
It was shown that ABT-263 targets Bcl-xL, Bcl-2 and Bcl-w in
the mitochondria and disrupts their interactions with Bad, Bax
and Bak proteins to initiate cancer cell death.22 We tested
whether ABT-263 affects these interactions in non-cancerous
IAV-infected human cells.Our immunofluorescence experiment
showed – and immuno-precipitation (IP) experiment confirmed
– that at non-cytotoxic concentrations, ABT-263 displaced Bad
from Bcl-xL and the mitochondria, and the IAV facilitated this
process (Figure 4 and Figure 5). Thus, ABT-263 can destabilise
the interaction of Bcl-xL, Bcl-2 and Bcl-w with Bad, Bax and Bak
in the mitochondria of non-cancerous cells infected with IAV.
In cells, the Bcl-xL, Bcl-2 and Bcl-w interactions are not
limited to Bad, Bax and Bak. Bcl-xL also interacts with
voltage-dependent anion-selective channel protein 1 (VDAC),
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Figure 2 ABT-263 and its structural analogues accelerate the death of cell lines infected with IAV and several other viruses. (a) Human monocyte-derived macrophages
were treated with ABT-263, ABT-737, ABT-199, gossypol or TW-37 and mock- or IAV-infected (WSN, moi 10), and DSS was estimated 11 h after infection. (b) Monocyte-
derived macrophages from seven volunteers were treated with ABT-263 and mock- or IAV-infected (WSN, moi 10), and DSS was estimated 11 h after infection. (c) Different
cell types were treated with ABT-263 and mock-infected or infected with different IAV strains (moi 10), and DSS was estimated 11 h after infection. (d) Different cell types were
treated with ABT-263 and mock-infected or infected with different viruses as indicated (moi from 2 to 10), and DSS was estimated. Echo6* – —for more details see
Supplementary Figure 2b
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Figure 3 Obatoclax and SaliPhe but not gemcitabine inhibit the ABT-263-mediated death of IAV-infected RPE cells. (a) RPE cells were treated with ABT-263 (0.4mM) and
with increasing concentrations of obatoclax, SaliPhe or gemcitabine. Cells were mock- or IAV-infected (WSN, moi 10), and cell viability was measured using a CTG assay 24 h
after infection. (b) RPE cells were treated with obatoclax (1mM), SaliPhe (1mM) or gemcitabine (10 mM) and with increasing concentrations of ABT-263. Cells were mock- or
IAV-infected (WSN, moi 10), and cell viability was measured using a CTG assay 24 h after infection. (c) RPE cells were IAV-infected (WSN, moi 10) and treated with ABT-263
(0.4mM) every hour. Cell viability was measured using a CTG assay 24 h after infection. (d) Schematic representation showing the stage of IAV replication cycle at which
ABT-263 triggers cell death. All error bars, s.d. (n¼ 3)
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Bcl-2-interacting mediator of cell death (Bim), DMN1L
(dynamin-1-like protein), Becn1 (beclin-1), PGAM5
(phosphoglycerate mutase 1), PUMA (p53 upregulated
modulator of apoptosis), p53, IKZF3 and HEBP2, whereas
Bcl-2 also interacts with APAF1, BNIPL, MRPL41, TP53BP2,
FKBP8, BAG1, RAF1, EGLN3 and G0S2.23,24 However, the
composition of Bcl-xL and Bcl-2 interactions could differ in
different cell types. A combination of IP and mass spectro-
metry revealed that Bcl-xL interacts with Bad, Bax and Bak, as
well as with UACA, PAWR, NUAK1, DAPK1, FLII, LRRFIP2,
TOLLIP, TRIM21, H2B, DHX9, 14-3-3, various cytoskeleton
proteins and viral HA (hemagglutinin), M1, NS1, NP (nucleo-
protein) proteins in RPE cells (Supplementary Tables). Bcl-xL
interactions with pattern recognition receptors (PPRs) such as
LRRFIP2, H2B and DHX9 indicate that Bcl-xL is potentially
involved in sensing viral nucleic acids, and Bcl-xL interactions
with FLII, TOLLIP and LRRFIP2 indicate that it could be also
involved in the Toll-like receptor 4 (TLR4) signalling cascade.
Thus, we identify novel interacting partners for Bcl-xL, and
possibly Bcl-2 and Bcl-w, which are specific but not limited to
human non-cancerous RPE cells.
The disruption of Bcl-xL, Bcl-2 and Bcl-w interactions with
newly identified partners by ABT-263 may contribute to IAV-
mediated death of cells. We tested the effect of ABT-263 on
interactions between Bcl-xL and its newly identified protein
partners in IAV- and mock-infected RPE cells. An SDS-PAGE
analysis of immuno-precipitated Bcl-xL-interacting proteins
demonstrated the differences in the protein compositions of
Bad
Bcl-xL
IAV IAV, ABT-263Mock, ABT-263Mock
MERGE
IAV IAV, ABT-263Mock, ABT-263Mock
Bad
Tom20
MERGE
Figure 4 Simultaneous ABT-263 treatment and IAV infection of RPE cells displace Bad from Bcl-xL and mitochondria. (a) RPE cells were non- or ABT-263-treated
(0.4mM) and mock- or IAV-infected (WSN, moi 30), fixed 6 h after infection, and Bad and Bcl-xL were imaged by an immunofluorescence assay. (b) RPE cells were treated as
in (a) and Bad and mitochondria (Tom20) were imaged using an immunofluorescence assay. Nuclei are stained by DAPI. Scale bars, 10 mm
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IPs (Figure 5b). Mass spectrometry, followed by an
immonoblot analysis of protein candidates, showed that
ABT-263, in combination with IAV, displaced UACA and Bax
from Bcl-xL, in addition to Bad (Figures 5a and b). Thus,
ABT-263 at non-cytotoxic concentrations alters the compo-
sition of Bcl-xL and perhaps of Bcl-2 and Bcl-w interactions
in IAV-infected cells (Figure 5c).
Both ABT-263 and IAV activate caspase-8, -9, -3 and -7 to
trigger cell death.5,25 We monitored the activation of caspase-8,
-9 and 3/7 in response to ABT-263 treatment and IAV
infection in RPE cells over time. We observed that a
combination of ABT-263 treatment and IAV infection resulted
in the enhancement of caspase-8, -9, -3 and -7 activities, and
this coincided with a decline of RPE cell viability (Figures 6a
and b). In IAV-infected cells, activated caspases cleaved their
substrates, such as Bid, and disrupted basic cellular pathways
and functions, which resulted in an inhibition of the transcrip-
tion and translation of cellular and viral mRNA and a reduction
in the production of infectious IAV virions (Supplementary
Figure 3). Thus, ABT-263 alters Bcl-xL, and perhaps Bcl-2
and Bcl-w interactions, and this activates caspase-8, -9, -3
and -7 to trigger the death of IAV-infected cells.
Interestingly, in RPE cells transfected with viral RNA
(vRNA), ABT-263 was also able to stimulate caspase-9, -3
and -7 activity and, weakly, caspase-8 (Figure 6c). The
caspase activation was dependent on the dose of ABT-263
and the concentration of transfected vRNA (data not shown).
However, this was insufficient to trigger the death of
vRNA-transfected RPE cells (Figure 6d). This indicates that
ABT-263 can trigger cell death in response to replicating virus.
To test whether ABT-263-mediated premature death of
infected cells alters the innate cellular immune responses, we
analysed the production of cytokines in IAV-infected RPE
cells in response to ABT-263 treatment (Figure 6e). Cytokine
profiling revealed that ABT-263 treatment attenuated the
IAV-mediated production of RANTES, interleukin (IL)-6, IL-8,
IP-10, CCL2 (C–C motif chemokine 2), CXCL1, interferon
(IFN)-b and IFN-l, but stimulated the production of IL1ra
(interleukin-1 receptor antagonist protein, IL-1F3). A similar
result was obtained with ABT-737 and ABT-199
(Supplementary Figure 4). Interestingly, in vRNA-transfected
RPE cells, ABT-263 was an ineffective inhibitor of RANTES,
IL-6, IL-8, IFN-b and IFN-l production because these cells
remained alive. Thus, ABT-263 induces premature death of
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Figure 5 Simultaneous ABT-263 treatment and IAV infection of RPE cells displaces Bad, Bax and UACA from Bcl-xL. (a) RPE cells were non- or ABT-263-treated
(0.4mM) and mock- or IAV-infected (WSN, moi 10), and total cell lysates were obtained 6 h after infection. Bad, Bax, UACA, LRRFIP2, FLII, TRIM21, Bcl-xL, NP and b-actin
(loading control) were analysed using western blotting in total lysates and immunoprecipitates by anti-Bcl-xL antibodies. (b) RPE cells were treated as in (a), lysates were
immuno-precipitated by anti-Bcl-xL antibodies and analysed using Coomassie staining. (c) Schematic representation showing a mechanism of ABT-263 action during IAV
infection 6 h after infection. ABT-263 is shown in orange
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virus-infected cells and limits the production of cellular
antiviral and pro-inflammatory responses.
ABT-263 lowers survival rates of IAV-infected mice by
imbalancing the host’s innate immune responses. We
tested the effect of ABT-263 in a standard mouse model for
influenza infection.26 Mice were challenged with one lethal
dose of mouse-adapted IAV, followed by a treatment with
50mg/kg ABT-263 three times at 12-h intervals. The
first dose of ABT-263 was given 48h after infection.
Kaplan–Meier survival curves showed that 100% of the
ABT-263-treated IAV-infected animals died (or had to be
euthanised due to excessive weight loss), whereas 60%
of IAV-infected mock-treated animals recovered from the
IAV infection (Figure 7a). The mouse survival rates were
dependent on the dose of ABT-263 and the viral load (data not
shown).
To further investigate the effect of ABT-263 treatment on
IAV-infected mice, four mice in each of the different treatment
groups were killed 6 days after infection, and the lungs were
collected. These lungs were used for histology as well as for
titration of the lung viral load, caspase activity and cytokine
levels. The ABT 263 treatment was ineffective in viral
replication (Figure 7b), caspase-3/7 activation (Figure 7c) or
lung inflammation (Figure 7d), compared with untreated
IAV-infected mice. We, however, observed a significant
imbalance in cytokine production in ABT-263-treated
IAV-infected mice in comparison with untreated IAV-infected
mice (Figures 7e and f). This imbalance likely resulted in
an inability of the immune system to clear the virus,
eventually leading to death of the virus-infected ABT-263-
treated animals.
Discussion
We here show that the anticancer ABT-263 and its structural
analogues ABT-199 and ABT-737 accelerate the death of
virus-infected cells and attenuate cellular antiviral and pro-
inflammatory responses. Based on our results, we propose a
mechanism of compound action in virus-infected non-cancer-
ous cells (Figure 8). In our model, ABT-263, ABT-199 and
ABT-737 bind Bcl-xL, Bcl-2 and Bcl-w and deactivate these
cellular ‘fuses’ by altering their interactions with pro-apoptotic
Bad, Bax and UACA in virus-infected cells. Bax and Bad
dissociation from the ‘fuses’ mediate the release of apopto-
genicmolecules, including cytochrome c, from themitochondria.
Cytochrome c forms complexes with ‘Bcl-xL-free’ UACA,
APAF1 and pro-caspase-9. Caspase-9 becomes activated in
this complex, empowering it to activate caspase-3 and -7
which, in turn, activates caspase-8. Caspase-8 is also
activated through a virus-induced FADD-mediated apoptosis
pathway. Active caspase-8 cleaves Bid, and the cleaved Bid
accelerates the mitochondrial caspase-9-mediated apoptosis
pathway. Thus, the mutual amplification of caspase-8, -9, -3
and -7 results in a dramatic increase of the quantity and
repertoire of proteolysed vital cell proteins, which potentiate
the transition of the apoptotic process to the execution ‘no
return’ phase of cell demise.
The premature cell death triggered by the inhibition of
Bcl-xL, Bcl-2 and Bcl-w prevents the development of cellular
antiviral and pro-inflammatory responses that are initiated by
cellular PPRs such as RIG-I (retinoic acid inducible gene-I)
and MDA5 in response to viral components.27–29 Surprisingly,
we found several PPRs (such as LRRFIP2, DHX9, H2B and
components of TLR4-signalling pathway such as FLII,
LRRFIP2 and TOLLIP) associated with Bcl-xL in mock- and
IAV-infected human RPE cells. This indicates that Bcl-xL,
Bcl-2 and Bcl-w regulate caspase-9-mediated apoptosis
through PPRs-mediated recognition of virus components
(such as vRNA).
We further observed an imbalance in cytokine production in
ABT-263-treated IAV-infected mice, associated with an
inability of the immune system to clear the virus, and
eventually lowering the survival rates of infected animals.
Note that mouse survival rates were dependent on the dose of
ABT-263 and viral load. Our results, nevertheless, warrant
against potential hazardous effects of therapeutic inhibition of
Bcl-xL, Bcl-2 and Bcl-w when using ABT-263 and its
derivatives in cancer patients with viral infections.
In conclusion, anticancer therapeutics may accelerate
or attenuate microbial infection in cancer patients by
targeting host functions essential for host–microbe interplay.
However, anticancer programs have neglected the
possibility of evaluating the effects of investigational small
molecules on this interplay. Preclinical trials are typically
performed on pathogen-free mice with xenotransplanted
human tumour cells, and early stages of clinical trials focus
on tumour regression and long-term survival without taking
into account the potential impact of the chemotherapeutic
agent in conjunction with underlying or overt viral infection of
the patients. Our study sets an example for addressing the
impact of anticancer molecules on the microbe–host interplay
and the therapeutic outcome in a background of microbial
infection.
Figure 6 Simultaneous ABT-263 treatment and IAV infection of RPE cells accelerates IAV-mediated apoptosis and dysregulates host cell cytokine production.
(a) RPE cells were non- or ABT-263-treated (0.4mM) and mock- or IAV-infected (WSN, moi 3), and caspase-3/7, -8 and -9 activity was measured at the indicated time points.
(b) RPE cells were non- or ABT-263-treated (0.4mM) and mock- or IAV-infected (WSN, moi 10), and cell viability was measured using a CTG assay at the indicated time
points. (c) RPE cells were mock or viral RNA (180 ng) transfected and non- or ABT-263-treated (0.4mM), and caspase-3/7, -8 and -9 activity was measured 24 h after
transfection. (d) RPE cells were treated as in (c), and cell viability was measured using the CTG assay 24 h after transfection. All error bars, s.d. (n¼ 3). (e) RPE cells were
treated as in (b), cell culture supernatants were collected 24 h after infection, and cytokine levels were determined using a human cytokine array panel A kit. (f) RPE cells were
treated as in (c), cell culture supernatants were collected 24 h after transfection, and cytokine levels were determined using a human cytokine array panel A kit. (g) RPE cells
were treated as in (b), and levels of RANTES, IL-6, IL-8, CCL2, IP-10 and IL1ra were determined using a human cytokine array panel A kit (n¼ 2) and (h) IFN-b and l were
determined by ELISA (n¼ 3). (i) RPE cells were treated as in (c), and levels of RANTES, IL-6, IL-8, CCL2, IP-10 and IL1ra were determined using a human cytokine array
panel A kit (n¼ 2) and (j) IFN-b and l were determined by ELISA (n¼ 3)
The adverse effects of ABT-263
L Kakkola et al
7
Cell Death and Disease
 0
20
40
60
80
100
0 2 4 6 8 10 12 14 16
Time (d)
Pr
ob
ab
ilit
y 
of
 s
ur
viv
al
 
(%
)
IAV
 or
 M
oc
k
AB
T-2
63
or
 Ca
rrie
r
Mock, ABT-263
Mock
 Ca
sp
as
e 
3/
7
(R
LU
, x
10
-
5 )
5
2
1
0
5
4
3
2
1
0
Mock, ABT-263 IAV, ABT-263Mock IAV
IP-10
R
el
at
iv
e 
in
te
ns
ity
 (%
)
R
e
la
tiv
e 
in
te
ns
ity
 (%
)
MCP-5
MIP-1α
MIP-1β
RANTES
TIMP-1
I-TAC IL-1ra
30
20
10
TREM-1
0
M-CSF
60
40
20
0
IL-1β
12
8
4
0
12
CXCL1
8
4
0
120
80
40
JE
0
IL-16
120
80
40
0
IFN-γ
60
40
20
0
C5/C5α
120
80
40
0
120
80
40
0
120
80
40
0
120
80
40
0
120
80
40
0
120
80
40
0
80
40
0
40
20
0
80
40
0
R
el
at
iv
e 
in
te
ns
ity
 
(%
)
R
el
at
iv
e 
in
te
ns
ity
 
(%
)
4
3
IAV:
ABT-263:
- +
- +
- +
- +
IAV:
ABT-263:
- +
- +
- +
- +
Vi
ru
s 
tit
er
(P
FU
/m
l, l
og
)
Mock, ABT-263
Mock
RS RS
Ne
gC
BL
C
C5
a
GC
SF
GM
CS
F
CC
L1
CC
L1
CD
54
IL1
?
IL1
?
IL1
ra
IL2
IL3 IL4 IL5 IL6 IL7 IL10 IL13IL12 IL16 IL17 IL23 IL27
IP10ITAC KC MCSF
TA
RC ?
RS
IFN
γ α β
CC
L2
MC
P5 MI
G
CC
L3
CC
L4
MI
P2
RA
NT
ES
CX
CL
12
TIM
P1
TN
Fα
TR
EM
1
IAV
IAV:
ABT-263:
- +
- +
- +
- +
- +
- +
- +
- +
- +
- +
- +
- +
- +
- +
- +
- +
IAV:
ABT-263:
- +
- +
- +
- +
- +
- +
- +
- +
- +
- +
- +
- +
- +
- +
- +
- +
IAV:
ABT-263:
- +
- +
- +
- +
- +
- +
- +
- +
- +
- +
- +
- +
- +
- +
- +
- +
IAV:
ABT-263:
- +
- +
- +
- +
- +
- +
- +
- +
- +
- +
- +
- +
- +
- +
- +
- +
IAV, ABT-263
IAV, ABT-263
IAV
The adverse effects of ABT-263
L Kakkola et al
8
Cell Death and Disease
Materials and Methods
Compounds, cells and viruses. ABT-263, ABT-737, gemcitabine, TW-37
and obatoclax were purchased from Selleck (Munich, Germany); ABT-199 were
purchased from Active Biochem (Bonn, Germany); and gossypol was purchased
from DTP/NCI. SaliPhe was provided by Jef De Brabander.30 All the compounds
were dissolved in 100% dimethyl sulfoxide (DMSO; Sigma-Aldrich, St. Louis, MO,
USA) to 10mM stock solutions and stored at  80 1C until use.
Human macrophages were differentiated from the peripheral blood mononuclear
cells isolated from healthy individuals and from buffy coats of the voluntary
blood donors from Finnish Red Cross as previously described.31 Human telomerase
reverse transcriptase-immortalized retinal pigment epithelial (hTERT-RPE),
Madin–Darby canine kidney (MDCK), monkey Vero-E6, human adenocarcinomic
alveolar basal epithelium (A549), doxycycline-inducible human endothelial
SLK cell line latently infected with a recombinant KSHV.219 (Kaposi’s
sarcoma-associated herpes virus) virus (iSLK.219) and baby hamster kidney
(BHK-21) cells were cultured as described.31,32 All cells were grown at 371C and
5% CO2.
The infection of macrophages, RPE, MDCK, A549, BHK-21 and Vero-E6 cells
with influenza A/WSN/33 (WSN; H1N1), A/PR/8/34 (PR8; H1N1), A/Sydney/5/1997
(Syd97; H3N2), B/Shandong/7/97 (InfB), human echovirus 6 (Echo6), sindbis
(SINV), semliki forest (SFV), bunyamwera (BUNV), measles (MeV), herpes simplex
1 and 2 (HSV-1, HSV-2), tick born encephalitis (TBEV), dengue (DENV) and
vaccinia (VACV) viruses was done as described previously.31,32 KSHV production
was induced in iSLK.219 cells with 0.2mg/ml doxycycline and 1.35mM sodium
butyrate.33 Titres of infectious viruses were determined as described.26,31
Compound efficacy testing in vitro. The compound efficacy testing was
performed in 96-well plates in human macrophages, RPE, A549, MDCK, Vero-E6
and iSLK.219 cells. Typically, cells were seeded in 100 ml of an appropriate cell
growth medium and grown for 24 h. The growth medium was changed to an
appropriate virus inoculum31 and the studied compounds were added into the
medium; DMSO was added to the control wells. The cells were infected with
viruses at a multiplicity of infection (moi) of 0.1–10 or non-infected (mock). Cell
viability was measured using a Cell Titre Glo assay (CTG; Promega,
Southampton, UK). Luminescence was read with PHERAstar FS plate reader
(BMG Labtech, Ortenberg, Germany).
We used drug sensitivity scoring (DSS) to calculate the efficacy of ABT-263.
Briefly, the dose–response curves were fitted based on a four-parameter logistic
model using the GraphPad Prism 5 software (http://www.graphpad.com/
scientific-software/prism/). Based on the estimated model parameters, quanti-
tative responses were calculated and expressed as DSS values. DSS
summarises the area under the dose–response curve over the entire dose
range relative to the total area between 10% of the threshold and 100% of
the inhibition. Further, to favour on-target responses over off-target responses, the
integrated response was divided by the logarithm of the bottom asymptote of the
logistic model. To assess the selective response of a compound to a virus-induced
cell death, a differential DSS was calculated by subtracting the mock control DSS
(no virus) from the viral DSS.
Compound efficacy testing in vivo. Specifically pathogen-free 6- to
7-week-old female BALB/c mice (Charles Rivers Laboratories, Lentilly, France)
were used. The animals were housed in a temperature-controlled environment
with 12-h light/dark cycles, and they received food and water ad libitum. Each
group contained 14 mice. Mice were inoculated intranasally with 50 ml PBS with or
without two LD50 of mouse-adapted A/PR/8/34 strain 26,34.26 At 48 hpi, mice
received the first oral dose of ABT-263, followed by two other doses at 12-h
intervals. ABT-263 was dosed at 50mg/kg in carrier (10% ethanol, 30%
polyethylene glycol 400 and 60% Phosal 50 PG); an equal volume of carrier only
was fed to the mock treatment group. This dosing of ABT-263 was based on
previously reported toxicity study on mice.22 Body weight was monitored daily and
mice that had lost more than 30% of their initial body weight were euthanised by
cervical dislocation. The survival data of the mouse experiments were analysed
using SigmaStat 11.0 and the Gehan–Breslow Test. Statistical significance tests
were performed with Student’s t-test; Po0.05 was considered significant.
Four mice per treatment group were euthanised on day 6 post-infection, and
lungs were collected. Lung homogenates were prepared from the right lobes in
1.5 ml of PBS using a microhomogeniser. The homogenate was cleared using
centrifugation at 13 800 g for 15min at 4 1C, and used for virus titre determination,
cytokine profiling and caspase activation assays (described below). The left lobes of
the lungs were fixed in neutral buffered 10% formalin, embedded in paraffin, cut with
a microtome and 4mm thick slices were stained with hematoxylin and eosin
(H&E-staining). Slides were imaged using Panoramic 250 Flash slide scanner
Figure 7 ABT-263 promotes the death of IAV-infected mice. (a) Kaplan–Meier survival curves of mice challenged with 50 ml PBS or two mouse LD50 doses of mouse-
adapted PR8 influenza strain and treated with a carrier or ABT-263 (50mg per kg body weight) in a carrier. (n¼ 10 mice). (b) Viral titres from mouse lung homogenates at day
6 in each treatment group (n¼ 4 mice). (c) Activity of caspase-3 and -7 in mouse lung homogenates at day 6 in each treatment group (n¼ 6 mice). (d) Representative
histochemical staining of lungs at day 6 in each treatment group. (e and f) Cytokine levels in mouse lung homogenates at day 6 in each treatment group were determined using
a mouse cytokine array panel A kit (n¼ 2). Error bars, s.d
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Figure 8 Potential mechanism of action of ABT-263 and its analogues in virus-infected cell
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(3DHistech, Hungary), and images were processed to virtual whole slides and
uploaded to the web server as previously described.35
Biochemical assays. Cytokine profiling was performed using mouse lung
homogenates or supernatants of compound-treated or non-treated, IAV-infected or
non-infected cells. Cytokine levels were measured using mouse or human cytokine
array panel A kits (R&D Systems, Minneapolis, MN, USA). Membranes were
exposed to X-ray film, and films were scanned. Each image was analysed using
the ImageJ software (http://rsbweb.nih.gov/ij/). In addition, the levels of TNF-a
(tumour necrosis factor), IFN-b and l in the cell supernatants were assayed with
ELISA (PBL Interferon Source).
Caspases 8, 9 and 3/7 activity were measured with Caspase-Glo-8, -9 and -3/7
assays (Promega). Actin, NS1 and PB2 mRNA levels were assayed with reverse-
transcription and strand-specific qPCRs as previously described.36 Production of
viral and cellular proteins was monitored using western blotting and autoradioauto-
graphy. Briefly, RPE cells were washed twice with PBS and covered with 50 ml
DMEM without methionine (Sigma-Aldrich) containing 10% BSA and S35
methionine (Perkin Elmer, Espoo, Finland), and incubated for 1 h at 37 1C. RPE
cells were washed twice with PBS, lysed in 2SDS-loading buffer and sonicated.
Lysates were loaded and proteins were separated on a gradient 4–20% SDS-
polyacrylamide gel (SDS-PAGE; Bio-Rad, Helsinki, Finland). S35-labelled proteins
were monitored using radioautography and visualised using a Typhoon 9400
scanner (GE Healthcare, Helsinki, Finland).
For a genomic viral RNA (vRNA) transfection experiment, A/WSN/33 virus was
grown in MDCK cells. Supernatants were collected at 24 hpi, and the virus was
pelleted using ultracentrifugation at 285 000 g for 4 h. Viral RNA was purified using
the RNA extraction kit (Qiagen, Hilden, Germany). The RNA was transfected into
RPE cells using Lipofectamine 2000 (Life Technologies, Carlsbad, CA, USA)
according to the manufacturer’s instructions. Six hours after transfection, the
Opti-MEM media were replaced with growth media with or without 0.4mM ABT-263.
After 18 h, the cell viability or caspase activity was measured.
Bcl-xL-associated factors were immuno-precipitated from infected and non-
infected, ABT-263-treated or non-treated RPE cells using rabbit anti-Bcl-xL (1 : 200;
cell signalling technology, Danvers, MA, USA) antibody as previously described.37
Immuno-precipitated proteins were separated with SDS-PAGE and visualised by
Coomassie staining. The entire lanes of SDS-PAGE were cut and the proteins were
in-gel digested with trypsin. Resulting peptides were analysed using liquid
chromatography–tandem mass spectrometry as previously described.38 The mass
spectrometry data were searched using in-house Mascot and the ProteinPilot
interface against the SwissProt database. All of the reported protein identifications
were statistically significant (Po0.05).
For immunoblotting, proteins were separated using SDS-PAGE and transferred
to a Hybond-LFP PVDF membrane. The membrane was blocked using 5% milk in
Tris-buffered saline (TBS) and incubated with a primary guinea pig anti-NS1
(1 : 2000), rabbit anti-Bcl-xL (1 : 1000; cell signalling technology), rabbit anti-Bid
(1 : 1000; cell signalling technology), rabbit anti-Bax (1 : 100; Santa Cruz
Biotechnology, Heidelberg, Germany), mouse anti-Bad (1 : 200; Santa Cruz
Biotechnology), rabbit anti-UACA (1 : 250; Sigma-Aldrich), rabbit anti-NP (1 : 500)
or mouse anti-b-actin (1 : 2000; Thermo Fisher Scientific, Dreieich, Germany)
antibody overnight at 4 1C. The membrane was washed three times for 10min with
TBS buffer containing 0.03% Tween 20 (Tween/TBS), and incubated for 4 h at 4 1C
with the respective secondary antibodies conjugated to infrared dyes 680LT or
800CW (1 : 20,000, Li-Cor Biosciences, Koge, Denmark). After three washes for
10min with Tween/TBS buffer and one with TBS, membranes were scanned using
an Odyssey scanner (Li-Cor Biosciences).
For immunofluorescence experiments ABT-263 (0.4mM) treated or non-treated
RPE cells were infected with A/WSN/33 at moi 30. At 6 hpi, cells were fixed with 4%
paraformaldehyde (in PBS). PBS with 1% BSA and 0.1% Triton X-100 was used for
blocking and permeabilisation of the fixed cells and for dilution of antibodies. For
detection of proteins, rabbit anti-Bcl-xL (1 : 200; clone 54H6; Cell Signalling
Technology), mouse anti-BAD (1 : 100; clone c-7; Santa Cruz Biotechnology), rabbit
anti-Tom20 (1 : 300; clone FL-145; Santa Cruz Biotechnology) antibodies were used.
Secondary antibodies were anti-mouse Alexa Fluor 594 or anti-rabbit Alexa Fluor 488
conjugated antibodies (1 : 2000 or 1 : 1000; Life Technologies). Nuclei were counter-
stained with DAPI. Images were captured using Nikon 90i microscope and processed
using the NIS Elements AR software (Nicon Instruments, Melville, NY, USA).
Ethical issues. Viral infections were carried out under BSL-2 conditions and
in compliance with regulations of the University of Helsinki (permit No 21/M/09).
Buffy coat fractions of voluntary blood donors were obtained under permission
from the Finnish Red Cross Blood Transfusion Service and approved by the
ethical review committee of the University of Helsinki Central Hospital, Finland
(165/13/03/00/2011). Collection of blood samples from volunteers was approved
by the ethical review committee of the University of Helsinki Central Hospital,
Finland (244/13/03/01/2012). Mouse influenza virus infection experiments were
carried out under BSL-2þ conditions and were authorised by the Institutional
Ethics Committee on Experimental Animals of the VIB Department for Molecular
Biomedical Research at Ghent University.
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